ArticleLung2021
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
Article in Lung, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03793439 (Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs.Acta dermato-venereologica · 2026Pooled it
- Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis.Thorax · 2025Pooled it
- Sarcoidosis: A Clinical Trials Perspective.Pulmonary therapy · 2026Review
- Oral Tofacitinib in Treatment of Cutaneous Sarcoidosis.Indian dermatology online journal · 2026Article
- A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.The Lancet. Respiratory medicine · 2026Review
- Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management.Open heart · 2026Article
- Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: A case series and a systematic review of the literature.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.Seminars in respiratory and critical care medicine · 2025Review
- Immunosuppressive Therapies in Pulmonary Sarcoidosis: A Practical, Evidence-Based Review.Journal of clinical medicine · 2025Review
- Tofacitinib-Induced Steroid-Free Remission in Subcutaneous Sarcoidosis With Neurologic Involvement: A Case Report.Cureus · 2025Article
- Sarcoidosis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Salvage use of tofacitinib in sarcoidosis patient with refractory multiorgan involvement.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Bioinformatic meta-analysis reveals novel differentially expressed genes and pathways in sarcoidosis.Frontiers in medicine · 2024Article
- Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.JID innovations : skin science from molecules to population health · 2023Review
- Simultaneous Assessment of mTORC1, JAK/STAT, and NLRP3 Inflammasome Activation Pathways in Patients with Sarcoidosis.International journal of molecular sciences · 2023Article
- Sarcoidosis-Related Uveitis: A Review.Journal of clinical medicine · 2023Review
- Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome.Frontiers in immunology · 2023Article
- The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy.American journal of clinical dermatology · 2022Review
- The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T cells, but not CD4 T cells.Journal of neuroimmunology · 2022Article
- LUNG Year in Review: 2021.Lung · 2022Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
This is a prospective, open-label, proof-of-concept study of tofacitinib, a Janus kinase inhibitor, as a steroid-sparing therapy in corticosteroid-dependent pulmonary sarcoidosis. Five patients with corticosteroid-dependent pulmonary sarcoidosis were treated with tofacitinib 5 mg twice daily. The primary endpoint was a ≥ 50% reduction in corticosteroids at week 16 with no worsening in pulmonary function or respiratory symptoms. 60% of patients (3/5) met the primary endpoint. One patient was lost to follow up prior to steroid taper, and another was withdrawn due to worsening of known neurosarcoidosis. The three patients who met the primary endpoint each tapered to ≤ 5 mg/day prednisone, respiratory symptoms improved, and spirometry remained stable. In this proof-of-concept study, the addition of a JAK-inhibitor allowed 60% of patients with pulmonary sarcoidosis to successfully taper corticosteroids. JAK-inhibitors are a promising therapy for pulmonary sarcoidosis, which require further investigation in randomized trials.Trial Registration clinicaltrials.gov NCT03793439; registered Jan 4, 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.